Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty

This article was originally published in PharmAsia News

Executive Summary

Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4

You may also be interested in...

Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents

Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.

Late-Stage Obesity Pipeline Is Stuffed With Mix Of Mechanisms

More Obesity Setbacks For Amylin And Takeda

Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts